Danielle Baruch, MD
Dermatology · Baltimore, MDNPI 1609296235
Payments from drug & device makers
Across 21 payments — averaging $21.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$124
- Novartis$61
- Almirall LLC$48
- Lilly USA, LLC$43
- Johnson & Johnson$42
- Regeneron Healthcare Solutions, Inc.$31
- plus $110 from 6 others
What the payments were for
- Food & beverage$459100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 4 | $124 |
| Novartis | 3 | $61 |
| Almirall LLC | 3 | $48 |
| Lilly USA, LLC | 2 | $43 |
| Johnson & Johnson | 1 | $42 |
| Regeneron Healthcare Solutions, Inc. | 1 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31 |
| Arcutis Biotherapeutics, Inc. | 1 | $20 |
| Dermavant Sciences, Inc. | 1 | $17 |
| AbbVie | 1 | $16 |
| Mayne Pharma Commercial LLC | 1 | $15 |
| Organon | 1 | $11 |
How this compares
$459 in reported general payments places this provider in the 25th percentile of 306 dermatology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 29 | $109,204 |
| OtezlaApremilast | 16 | $76,013 |
| Dupixent SyringeDupilumab | 19 | $69,058 |
| Clobetasol Propionate | 154 | $9,209 |
| Fluocinonide | 66 | $2,342 |
| Tacrolimus | 16 | $2,243 |
| Fluorouracil | 27 | $2,223 |
| Metronidazole | 41 | $1,845 |
| Clindamycin Phosphate | 31 | $1,160 |
| Triamcinolone Acetonide | 79 | $1,104 |
| Dutasteride | 45 | $1,022 |
| Ammonium Lactate | 51 | $1,000 |
| Halobetasol Propionate | 14 | $861 |
| Ketoconazole | 59 | $772 |
| Finasteride | 58 | $642 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Baltimore
- Shawn KwatraBaltimore$2.4M
- Lloyd MillerBaltimore$752K
- Luis GarzaBaltimore$533K
- Sima RozatiBaltimore$385K
- Crystal AguhBaltimore$187K
- Tamia Harris-TryonBaltimore$128K
- Elizabeth TanziBaltimore$59K
- Anthony GaspariBaltimore$45K
- Sewon KangBaltimore$44K
- Jun KangBaltimore$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.